CompletedNot Applicable

Role of Eosinophil in Fibrogenesis of Systemic Sclerosis

France70 participantsStarted 2018-10-03

Plain-language summary

Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases. Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications. The profibrosing properties and data from the SSc literature suggest a possible role of the eosinophils in the process of fibrogenesis of SSc.

Who can participate

Age range18 Years – 66 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For SSc patients: * Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20) * Having signed the informed consent * Eosinophils ≥ 0.1 G / L on the last blood test (\<3 months) For healthy subjects: * Without chronic pathology requiring long-term treatment * Eosinophils between 0.1 and 0.4 G / L on recent blood test (\<3 months) Exclusion Criteria for patients and controls: * Patient with an infection, state of emergency or progressive neoplastic pathology * Pregnant or lactating women * History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic conjunctivitis) * Allergy to local anesthetics (for scleroderma patients only) * Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory effects of scleroderma, only patients with at least 10 g of hemoglobin will be included

What they're measuring

Comparison of ECP concentrations in supernatants of eosinophils culture

Timeframe: Baseline: one session

Trial details

NCT IDNCT03816189

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-05

View on ClinicalTrials.gov More Systemic Sclerosis trials